$CNC

2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation

Centene Corp. (CNC) and Archer-Daniels-Midland Co. (ADM) are highlighted for strong performance and attractive valuations. CNC expects 2026 revenues of $173-$177B and adjusted EPS over $4.80, with a forward P/E of 13.58X. ADM raised 2026 adjusted earnings guidance to $5.15-$5.60 per share, with a forward P/E of 16.60X.

Original reporting
Published Sep 15, 2026, 12:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
2 Non-AI Giants to Buy on Solid Guidance and Lucrative Valuation — source image
Decision brief

The 30-second read

$CNCBullishMed
01

Why it matters

New guidance lifts earnings expectations, which could drive price appreciation, but investors should monitor policy and commodity risks.

02

Market read

Guidance upgrades for CNC and ADM provide fresh material for traders seeking upside in healthcare and agribusiness sectors.

03

What to watch

Potential headwinds from Medicaid policy changes and commodity price volatility could temper gains.

Relevance 7/10Novelty 7/10Timing: guidance update released today

Background

The article highlights two non‑AI stocks with strong Zacks Rank #1 and updated 2026 guidance, positioning them as attractive buys for the remainder of the year.

Company-level read

Ticker impact

$CNCBullishHigh confidence
Context

Centene Corp. raised its 2026 revenue guidance to $173‑$177 B and adjusted EPS to >$4.80, a fresh update disclosed in this article.

Expected impact

Potential upside of 5‑10% over the next weeks if market digests the guidance.

Evidence & confidence

Guidance beats prior expectations and EPS outlook improves >130%, indicating strong upside.

$ADMBullishHigh confidence
Context

Archer‑Daniels‑Midland announced 2026 adjusted earnings guidance of $5.15‑$5.60 per share, up from $4.15‑$4.70, a new disclosure.

Expected impact

Expect modest rally of 3‑7% as investors price in higher earnings.

Evidence & confidence

Guidance increase reflects better margins from renewable fuel obligations and higher energy prices.

Market effects

Both healthcare and agribusiness sectors may see uplift as peers' guidance improves.

U.S. markets could see modest gains in related ETFs tracking health services and commodities.

Positive guidance may reinforce confidence in AI‑linked growth themes globally.

Counterpoint

If guidance improvements are already priced in, the stocks may face limited upside.

Key entities

  • Centene Corp.

    U.S. healthcare services provider

  • Archer‑Daniels‑Midland Co.

    U.S. agribusiness and food processing company

Related articles

$ADMMed

CJ CheilJedang partners with ADM to boost U.S. lysine output amid China curbs

CJ CheilJedang (097950) and ADM formed a joint venture to boost U.S. lysine production, with CJ holding a 63% stake. The move aims to compete with Chinese lysine amid tightened trade restrictions. CJ will contribute its U.S. and Brazil facilities, while ADM will provide its Illinois plant and raw material network. Lysine prices have rebounded due to trade actions against China, with U.S. prices up 38% since December.

$ADMMed

Amino Acids Venture Might Change The Case For Investing In ADM Stock

Archer-Daniels-Midland (ADM) and CJ CheilJedang formed a joint venture to produce and sell feed-grade amino acids in the Americas. The deal, with CJ as majority owner, includes ADM's Decatur facility. Analysts expect ADM's revenue to grow 2.8% annually to $89.2B by 2029, with earnings rising to $2.3B. The joint venture is part of ADM's broader strategy to focus on fermentation-based offerings and animal nutrition.

$CNCHigh

ACA fraud crackdown threatens health insurer profits in 2026

Vice President JD Vance announced 760,000 ACA enrollees were dropped due to fraud, with 400,000 under review. Insurers like Centene, Molina, Elevance, and UnitedHealth saw stock declines. Experts warn of squeezed margins in 2026-2027 due to a less healthy risk pool. Premium rates for 2027 are locked, and insurers may push for higher 2028 rates. Brokers, who drive 75% of sign-ups, face new restrictions and potential reputational damage.

$ADMMedAI 8/10

CJ CheilJedang and ADM form amino acid joint venture

CJ CheilJedang (KRX:097950) and ADM (NYSE:ADM) agreed to form a joint venture to produce and market feed-grade amino acids in the Americas. CJ will license its technology and hold majority ownership. The venture will use facilities in Iowa, Illinois, and Brazil, aiming to enhance cost competitiveness and support U.S. production.